Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06758713 | Jan 2025 → Dec 2028 expected | plasma cell myeloma | The Third Affiliated Hospital of Southern Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06758713 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy involves autologous chimeric antigen receptor T-cells” NCT06758713 ↗ |
| Target | CD19 | “capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies” NCT06758713 ↗ |